{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Apap Mangion S"],"funding":["Rosetrees Trust","Multiple Sclerosis Society - UK","National Multiple Sclerosis Society - US","National Institute for Health and Care Research"],"pagination":["e71101"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12657254"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(12)"],"pubmed_abstract":["Background
People with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9-hole peg test (9HPT) is the primary clinical measure for ULD but does not fully capture the patient experience. The ABILHAND-23 is a well-validated patient-reported outcome measure (PROM) that evaluates bimanual ability in daily function. However, no large-scale studies have assessed if the 9HPT reflects the individual ULD experience in pwPMS.Objectives
We sought to (van Munster et al. 2023) assess the associations between the ABILHAND-23 and 9HPT, and (Huertas-Hoyas et al. 2020) to assess the ability of the 9HPT and other relevant covariables to predict ABILHAND-23 scores, using baseline"],"journal":["Brain and behavior"],"pubmed_title":["The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test."],"pmcid":["PMC12657254"],"funding_grant_id":["HTA Project: 15/57/143"],"pubmed_authors":["Nicholas J","Bianchi A","Farrell R","Leibowitz M","Braisher M","Favarato G","Oraluzume O","John N","Wright S","Apap Mangion S","Blackstone J","Angelis F","Vecchio G","Calvi A","Wade C","Williams T","UCL MS‐STAT2 Investigators","Chataway J","Doshi A"],"additional_accession":[]},"is_claimable":false,"name":"The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test.","description":"Background
People with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9-hole peg test (9HPT) is the primary clinical measure for ULD but does not fully capture the patient experience. The ABILHAND-23 is a well-validated patient-reported outcome measure (PROM) that evaluates bimanual ability in daily function. However, no large-scale studies have assessed if the 9HPT reflects the individual ULD experience in pwPMS.Objectives
We sought to (van Munster et al. 2023) assess the associations between the ABILHAND-23 and 9HPT, and (Huertas-Hoyas et al. 2020) to assess the ability of the 9HPT and other relevant covariables to predict ABILHAND-23 scores, using baseline","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T19:55:04.191Z","creation":"2026-05-21T03:11:46.823Z"},"accession":"S-EPMC12657254","cross_references":{"pubmed":["41299878"],"doi":["10.1002/brb3.71101"]}}